| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
41,504,000 |
| Market
Cap: |
1.91(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$24.67 - $47.35 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 572 |
| Guru Rank Value : 3.2 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Collegium Pharmaceutical is a pharmaceutical company. Co.'s portfolio includes: Xtampza ER, Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol. Xtampza ER was approved by the U.S. Food and Drug Administration for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
82,331 |
152,246 |
347,770 |
692,579 |
| Total Sell Value |
$3,532,865 |
$6,093,975 |
$11,888,903 |
$23,130,269 |
| Total People Sold |
3 |
7 |
8 |
10 |
| Total Sell Transactions |
3 |
9 |
26 |
42 |
| End Date |
2025-08-19 |
2025-05-18 |
2024-11-17 |
2023-11-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fallon John A. |
|
– • – |
2025-11-12 |
4 |
S |
$47.21 |
$1,645,536 |
D/D |
(34,853) |
64,634 |
|
- |
|
| Fallon John A. |
|
– • – |
2025-11-12 |
4 |
OE |
$9.33 |
$432,578 |
D/D |
34,853 |
99,487 |
|
- |
|
| Karnani Vikram |
President and CEO |
• • – |
2025-11-12 |
4 |
D |
$47.35 |
$425,345 |
D/D |
(8,983) |
96,989 |
|
- |
|
| Tupper Colleen |
EVP & Chief Financial Officer |
• – – |
2025-11-06 |
4 |
AS |
$40.38 |
$1,215,753 |
D/D |
(30,000) |
126,667 |
|
13% |
|
| Smith Thomas B |
EVP and Chief Medical Officer |
• – – |
2025-08-29 |
4 |
S |
$38.42 |
$671,576 |
D/D |
(17,478) |
70,264 |
|
-20% |
|
| Dreyer Scott |
EVP & Chief Commercial Officer |
• – – |
2025-08-18 |
4 |
AS |
$38.21 |
$626,171 |
D/D |
(16,389) |
103,613 |
|
20% |
|
| Dreyer Scott |
EVP & Chief Commercial Officer |
• – – |
2025-08-18 |
4 |
OE |
$21.34 |
$349,741 |
D/D |
16,389 |
120,002 |
|
- |
|
| Santini Gino |
Director |
– • – |
2025-08-15 |
4 |
S |
$37.19 |
$201,018 |
D/D |
(5,405) |
95,042 |
|
-23% |
|
| Santini Gino |
Director |
– • – |
2025-08-15 |
4 |
OE |
$13.45 |
$201,750 |
D/D |
15,000 |
100,447 |
|
- |
|
| Dreyer Scott |
EVP & Chief Commercial Officer |
• – – |
2025-08-13 |
4 |
AS |
$38.03 |
$184,881 |
D/D |
(4,861) |
103,613 |
|
21% |
|
| Dreyer Scott |
EVP & Chief Commercial Officer |
• – – |
2025-08-13 |
4 |
OE |
$21.34 |
$103,734 |
D/D |
4,861 |
108,474 |
|
- |
|
| Rosen David Efraim |
10% Owner |
– – • |
2025-08-13 |
4 |
S |
$37.85 |
$946,250 |
I/I |
(25,000) |
3,132,743 |
|
-23% |
|
| Freund John Gordon |
Director |
– • – |
2025-08-08 |
4 |
S |
$34.36 |
$400,641 |
I/I |
(11,659) |
23,129 |
|
-33% |
|
| Rosen David Efraim |
10% Owner |
– – • |
2025-08-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,157,743 |
|
41% |
|
| Freund John Gordon |
Director |
– • – |
2025-06-09 |
4 |
S |
$30.62 |
$202,149 |
D/D |
(6,601) |
70,658 |
|
-9% |
|
| Freund John Gordon |
Director |
– • – |
2025-06-09 |
4 |
OE |
$13.45 |
$201,750 |
D/D |
15,000 |
77,259 |
|
- |
|
| Bohlin Garen G |
Director |
– • – |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,791 |
62,259 |
|
- |
|
| Lurker Nancy |
Director |
– • – |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,791 |
22,517 |
|
- |
|
| Freund John Gordon |
Director |
– • – |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,791 |
62,259 |
|
- |
|
| Santini Gino |
Director |
– • – |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,791 |
85,447 |
|
- |
|
| Fallon John A. |
Director |
– • – |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,791 |
64,634 |
|
- |
|
| Paya Carlos V |
Director |
– • – |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
19,582 |
19,582 |
|
- |
|
| Balice-Gordon Rita J. |
Director |
– • – |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,791 |
56,279 |
|
- |
|
| Dreyer Scott |
EVP & Chief Commercial Officer |
• – – |
2025-03-21 |
4 |
AS |
$30.03 |
$566,983 |
D/D |
(18,881) |
103,613 |
|
-1% |
|
| Tupper Colleen |
EVP & Chief Financial Officer |
• – – |
2025-03-21 |
4 |
AS |
$30.03 |
$192,069 |
D/D |
(6,396) |
156,667 |
|
-1% |
|
446 Records found
|
|
Page 1 of 18 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.40 (0.86%) 
